Telmisartan + amlodipine + indapamide

Telmisartan + amlodipine + indapamide decreases systolic blood pressure in humans (hypertension; placebo-controlled trial) (Maximum reduction within 1 week; no apparent additional reduction thereafter.).

“SBP was reduced rapidly, with the maximum decrement occurring within 1 week after randomization and no apparent additional reduction thereafter.”

Human trialhypertension; placebo-controlled trialsingle-pill combination10/1.25/0.625 or 20/2.5/1.25 mg/d4 weeks

Time course of onset and offset of blood pressure reduction with a novel low-dose triple single pill combination

ESC Congress 2026 abstract·Oct 26, 2026

Telmisartan + amlodipine + indapamide decreases systolic blood pressure in humans (prior intracerebral hemorrhage; added to usual care versus matching placebo) (15/7 mmHg systolic/diastolic reduction versus placebo at 6 weeks; 9/4 mmHg averaged over all follow-up).

“The overall BP difference at 6 weeks was 15/7 mmHg and averaged 9/4 mmHg over all follow-up”

Human trialprior intracerebral hemorrhage; added to usual care versus matching placebotriple-pilltelmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg6 weeks34% femalesn = 1,670

Low-dose triple pill lowered blood pressure alone or added on

ESC Congress 2026 abstract·Oct 26, 2026

Telmisartan + amlodipine + indapamide decreases blood pressure variability in humans (Systolic SD difference −2.05 mmHg (95% CI −2.73 to −1.36); diastolic SD difference −0.84 mmHg (95% CI −1.24 to −0.43); VIM unchanged).

“a low-dose triple single-pill combination reduced SD, CV and ARV of systolic and diastolic BP variability compared with placebo, but not VIM.”

Human trialPrior intracerebral hemorrhage; added to usual care versus placebo; reductions in SD, CV and ARV, but not VIMSingle-pill combinationTelmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mgMean follow-up of 3 years33% femalesn = 1,557

Three-drug pill reduced blood pressure swings after brain bleed

ESC Congress 2026 abstract·Oct 26, 2026